UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis
· Topline results are expected in the first half of 2024 · Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet medical need exists for safe oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2 results in psoriasis and hidradenitis suppurativa (HS) Hellerup, Denmark, November 16, 2023 – UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious